Recurrent triple-negative breast cancer (TNBC) tissues contain a higher amount of phosphatidylcholine (32:1) than non-recurrent TNBC tissues

被引:35
|
作者
Hosokawa, Yuko [1 ,2 ,3 ]
Masaki, Noritaka [2 ,3 ]
Takei, Shiro [2 ,3 ]
Horikawa, Makoto [2 ,3 ]
Matsushita, Shoko [2 ,3 ]
Sugiyama, Eiji [2 ,3 ]
Ogura, Hiroyuki [1 ]
Shiiya, Norihiko [1 ]
Setou, Mitsutoshi [2 ,3 ,4 ,5 ,6 ]
机构
[1] Hamamatsu Univ, Sch Med, Dept Surg 1, Higashi Ku, Hamamatsu, Shizuoka, Japan
[2] Hamamatsu Univ, Sch Med, Int Mass Imaging Ctr, Higashi Ku, Hamamatsu, Shizuoka, Japan
[3] Hamamatsu Univ, Sch Med, Dept Cellular & Mol Anat, Higashi Ku, Hamamatsu, Shizuoka, Japan
[4] Preeminent Med Photon Educ & Res Ctr, Higashi Ku, Hamamatsu, Shizuoka, Japan
[5] Univ Hong Kong, Dept Anat, 6-F,William MW Mong Block,Sassoon Rd, Pokfulam, Hong Kong, Peoples R China
[6] RIKEN, Ctr Mol Imaging Sci, Chuo Ku, Kobe, Hyogo, Japan
来源
PLOS ONE | 2017年 / 12卷 / 08期
关键词
MASS-SPECTROMETRY; SURVIVAL;
D O I
10.1371/journal.pone.0183724
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Triple-negative breast cancer (TNBC) is one of the breast cancer subtype that displays a high risk of early recurrence and short overall survival. Improvement of the prognosis of patients with TNBC requires identifying a predictive factor of recurrence, which would make it possible to provide beneficial personalized treatment. However, no clinically reliable predictive factor is currently known. In this study, we investigated the predictive factor of recurrence in TNBC using matrix-assisted laser desorption/ionization-imaging mass spectrometry for lipid profiling of breast cancer specimens obtained from three and six patients with recurrent and non-recurrent TNBC, respectively. The signal for phosphatidylcholine (PC) (32:1) at m/z 732.5 was significantly higher in the recurrence group compared to the non-recurrence group (P = 0.024). PC (32:1) was more abundant in the cancer epithelial area than it was in the surrounding stroma, suggesting that abnormal lipid metabolism was associated with malignant transformation. Our results indicate PC (32:1) as a candidate predictive factor of TNBC recurrence. A future prospective study investigating whether personalized therapy based on PC (32:1) intensity improves the prognosis of patients with TNBC is recommended.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Chemokine network between triple-negative breast cancer (TNBC) and non-TNBC cells.
    Gibbs, Carla
    Ignacio, Rosa
    Hyeong, Choi
    Son, Deok-Soo
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2018, 27 (07) : 88 - 89
  • [2] Recurrent versus non-recurrent triple negative breast cancer: An institutional study
    Akpoviroro, Ogheneyoma
    Sauers, Nathan Kyle
    Uwandu, Queeneth
    Ahmed, Sameer
    Humayun, Sara
    Castagne, Myriam
    Srinivasa, Hema Malini
    Mirza, Wasique
    Sharma, Namita
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer (TNBC).
    Afghahi, Anosheh
    Rigdon, Joseph
    Purington, Natasha
    Desal, Manisha
    Pierson, Emma
    Mathur, Maya
    Thompson, Caroline A.
    Curtis, Christina
    West, Robert B.
    Horst, Kathleen C.
    Gomez, Scarlett Lin
    Ford, James M.
    Sledge, George W.
    Kurian, Allison W.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Cellular localization of PRMT5 correlates with poor recurrent free survival in triple-negative breast cancer (TNBC)
    Alexander, Elaine P.
    Earl, Christian T.
    Mo, Xiaokui
    Shilo, Konstantin
    Baiocchi, Robert A.
    Lustberg, Maryam B.
    CANCER RESEARCH, 2015, 75
  • [5] Outcomes of triple-negative breast cancer (TNBC) versus non-TNBC patients: Does the survival vary for all stages?
    Agarwal, Gaurav
    Nanda, Gitika
    Lal, Punita
    Agrawal, Sushma
    Krishnani, Narendra
    Kumari, Niraj
    Chand, Gyan
    Mishra, Anjali
    Agarwal, Amit
    Verma, Ashok Kumar
    Mishra, Saroj Kanta
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Dual targeting of αv and α5β1 integrins in triple-negative breast cancer (TNBC)
    Song, Fei
    Do, Kevin
    Fein, Daniel E. C.
    Jahanseir, Narges
    Joshi, Raghav
    Mathew, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy
    Kim, Sanghwa
    Park, Hyung Seok
    Kim, Jee Ye
    Ryu, Jegyu
    Park, Seho
    Kim, Seung Il
    YONSEI MEDICAL JOURNAL, 2016, 57 (05) : 1192 - 1198
  • [8] Folate receptor alpha (FOLR1) expression in triple-negative breast cancer (TNBC)
    Cui, X.
    McIntire, P. J.
    Ginter, P. S.
    Irshaid, L.
    Chen, Z.
    Shin, S. J.
    CANCER RESEARCH, 2017, 77
  • [9] Triple-negative breast cancer (TNBC) and residual disease (non-pCR): Does size matter?
    Kern, Peter
    Badiian, Mahyar
    Minckwitz, Gunter
    Kimmig, Rainer
    Liedtke, Cornelia
    Rezai, Mahdi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [10] A Retrospective Pilot Study of Longitudinal Molecular Discordance of Primary versus Recurrent Triple Negative Breast Cancer (TNBC).
    Yuan, Yuan
    Wu, Xiwei
    Yos, Susan
    Wang, Jinhui
    Yang, Lu
    Goldstein, Leanne
    Liu, Zheng
    Yuan, Yate-Ching
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)